PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Amantadine hydrochloride - Parkinson's disease

PAD Profile : Amantadine hydrochloride - Parkinson's disease

Keywords :
Parkinsons disease, PD, dopamine agonists

Traffic Light Status

Status 1 of 1.

Status :
Blue
Formulations :
  • Capsules
  • Oral solution
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
06 June 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Amantadine may be considered as an adjuvant where dyskinesia is not adequately managed by modifying existing therapy.

Initiation may be carried out in Primary Care but only after recommendation by a specialist.

Modifications to therapy should only be carried out on specialist advice.

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More